Authors:
Behe, M
Du, J
Becker, W
Behr, T
Angerstein, C
Marquez, M
Hiltunen, J
Nilsson, S
Holmberg, AR
Citation: M. Behe et al., Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate, MED ONCOL, 18(1), 2001, pp. 59-64
Authors:
Gratz, S
Behe, M
Boerman, OC
Kunze, E
Schulz, H
Eiffert, H
O'Reilly, T
Behr, TM
Angerstein, C
Nebendahl, K
Kauer, F
Becker, W
Citation: S. Gratz et al., Tc-99m-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model, NUCL MED C, 22(9), 2001, pp. 1003-1013
Authors:
Behr, TM
Behe, M
Lohr, M
Sgouros, G
Angerstein, C
Wehrmann, E
Nebendahl, K
Becker, W
Citation: Tm. Behr et al., Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies, EUR J NUCL, 27(7), 2000, pp. 753-765
Authors:
Behr, TM
Sgouros, G
Stabin, MG
Behe, M
Angerstein, C
Blumenthal, RD
Apostolidis, C
Molinet, R
Sharkey, RM
Koch, L
Goldenberg, DM
Becker, W
Citation: Tm. Behr et al., Studies on the red marrow dosimetry in radioimmunotherapy: An experimentalinvestigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters, CLIN CANC R, 5(10), 1999, pp. 3031S-3043S
Authors:
Behr, TM
Behe, M
Angerstein, C
Gratz, S
Mach, R
Hagemann, L
Jenner, N
Stiehler, M
Frank-Raue, K
Raue, F
Becker, W
Citation: Tm. Behr et al., Cholecystokinin-B/gastrin receptor binding peptides: Preclinical development and evaluation of their diagnostic and therapeutic potential, CLIN CANC R, 5(10), 1999, pp. 3124S-3138S
Authors:
Behr, TM
Salib, AL
Liersch, T
Behe, M
Angerstein, C
Blumenthal, RD
Fayyazi, A
Sharkey, RM
Ringe, B
Becker, H
Wormann, B
Hiddemann, W
Goldenberg, DM
Becker, W
Citation: Tm. Behr et al., Radioimmunotherapy of small volume disease of colorectal cancer metastaticto the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study, CLIN CANC R, 5(10), 1999, pp. 3232S-3242S